Completed PHASE2 INTERVENTIONAL NCT00140803

Study Of Combined VISUDYNE Therapy With Kenalog In CNV Secondary To Age-Related Macular Degeneration

A Randomized, Single-Masked, Multi-Center, Phase 2 Evaluation Of The Effect Of PDT Using Visudyne In Combination With Intravitreal Injection Of Either 0 mg, 1mg or 4mg of Kenalog In Subfoveal Occult & Minimally Classic CNV Secondary To ARMD

Sponsor: Manhattan Eye, Ear & Throat Hospital

Conditions Age-Related Macular Degeneration

Interventions Kenalog Visudyne

Updated 5 times since 2017 Last updated: Jul 11, 2007 Started: Oct 31, 2003 Completion: Jan 31, 2007

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Age-Related Macular Degeneration, this trial is completed. The trial is conducted by Manhattan Eye, Ear & Throat Hospital and has accumulated 5 data snapshots since 2003. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Oct 2003

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Manhattan Eye, Ear & Throat Hospital
Novartis
QLT Inc.

Data source: Manhattan Eye, Ear & Throat Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• New York, United States
• Vancouver, Canada